

**South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2020 - September 30, 2021**

Department	Project Number	Project Title	Principal Investigator	Source of Funding	20-21 Receipts
Internal Medicine					
	63824	Uptravi (Selexipag): tHe usErs dRug rEgistry (Actelion AC-065A402 Sphere Registry)	Dr Fagan, K	Actelion Pharmaceuticals US, Inc.	6,500.00
	63842	A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency (HEART-FID) (Luitpold - 1VIT15043)	Dr Malozzi, C	Luitpold Pharmaceuticals, Inc.	15,598.00
	63878	An Open Label Phase 2 Study to Characterize Colon Pathology in Patients with HER2 Amplified Breast Cancer Treated with Neratinib (PUMA-NER-6203)	Dr DiPalma, J	Puma Biotechnology, Inc.	42,900.00
	63891	Corrona Inflammatory Bowel Disease (IBD) Registry (IBD-600 Registry)	Dr Sonnier, W	Corrona, LLC	7,600.00
	63896	A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID19 (AstraZeneca CALAVI D822FC00003)	Dr Fouty, B	Acerta Pharma B.V. (AstraZeneca)	15,281.00
				Total Internal Medicine	87,879.00

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2020 - September 30, 2021

Department	Project Number	Project Title	Principal Investigator	Source of Funding	20-21 Receipts
Neurology	63785	Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another approved disease-modifying therapy (Novartis FTY720D 2403)	Dr Minto, E	Novartis	5,230.80
	63868	CLadribine tablets: Observational evaluation of effectiveness and patient-reported outcomes (PROs) in suboptimally Controlled patients previously taking injectable disease-modifying drugs (DMDs) for relapsing forms of Multiple Sclerosis (RMS) (CLICK-MS) (EMD Serono MS700568_0078)	Dr Kilgo, W	EMD Serono, Inc.	2,000.00
	63885	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety (EMD Serono Ms200527_0080)	Dr Kilgo, W	EMD Serono, Inc.	8,700.00
	63886	A Multicenter, Longitudinal, Open-label, Single-arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (Celgene RPC-1063-MS-001)	Dr Kilgo, W	Celgene International II Sarl	20,460.00
	63888	A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients (AbbVie M15-736)	Dr Dees, D	AbbVie, Inc.	40,877.38
	63894	Advanced Parkinson's Disease: An Open-Label Extension Study of M15-736 Evaluating the Safety and Tolerability of ABBV-951 (AbbVie M20-098)	Dr Dees, D	AbbVie, Inc.	14,150.00
	63897	A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) (Alexion ALXN1210-NMO-307)	Dr Kilgo, W	Alexion Pharmaceuticals, Inc.	11,800.00
	63898	Success in Comaneci-assist Coils Embolization Surveillance Study (Rapid Medical Postmarket Surveillance)	Dr Cordina, S	Rapid Medical	8,250.00
				Total Neurology	111,468.18

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2020 - September 30, 2021

Department	Project Number	Project Title	Principal Investigator	Source of Funding	20-21 Receipts
OB-GYN					
	63887	A Phase 3, Randomized, Double- or Observer-Blinded, Placebo-Controlled Trial to Evaluate The Efficacy and Safety of a Respiratory Syncytial Virus (RSV) Perfusion FSubunit Vaccine in Infants Born to Women Vaccinated During Pregnancy Investigational (Pfizer C3671008)	Dr Roth, T	Pfizer	17,878.64
				Total OB-GYN	17,878.64
Pediatrics					
	63876	Effects of an Exclusive Human Milk Diet on Enteral Feeding Outcomes of Neonates with Congenital Gastrointestinal Disorders (Prolacta CGD)	Dr Eyal, F	Prolacta Bioscience	9,327.50
	63895	A Phase II, multicenter, double blind, double dummy, randomized, 2 arms parallel study to evaluate the efficacy, safety and pharmacokinetics of CHF6563 in babies with Neonatal Opioid Withdrawal Syndrome (Chiesi CLI-06563AA1-02)	Dr Whitehurst, R	Chiesi Farmaceutici	12,385.00
				Total Pediatrics	21,712.50

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2020 - September 30, 2021

Department	Project Number	Project Title	Principal Investigator	Source of Funding	20-21 Receipts
Surgery	63857	TAK-954-2004: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperative Gastrointestinal Dysfunction in Patients Undergoing Large- and Small-bowel Resection (Millennium TAK-954-2004)	Dr Rider, P	Millennium Pharmaceuticals / Takeda	41,340.68
	63879	Use of Nexobrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries (MediWound MW2018-06-21)	Dr Bright, A	Mediwound	71,396.19
	63889	A Phase 2, multicenter, randomized, double-blind, placebo-controlled study of naldemedine in patients undergoing surgeries that include a bowel resection or bowel transection	Dr Hunter, J	Shionogi, Inc.	10,700.00
					Total Surgery
Mitchell Cancer Institute	63752	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects with Stage IIIb-IV Ovarian Cancer in Clinical Complete Response following Surgery and Primary Chemotherapy (VITAL) - (CL-PTL-119) (Gradalis CL-PTL-119)	Dr Rocconi, R	Gradalis, Inc.	3,615.00
	63799	PALLAS PALbociclib CoLLaborative Adjuvant Study: A radomized phase III trial of Palbociclib with standard adjuvant endorine therapy versus standard adjuvant endocrine therapy alone for hormone receptor 2 (HER2) negative early breast cancer (Alpha PrE0109 - PALLAS)	Dr Heslin, M	Alliance Foundation Trials, LLC (Pfizer)	7,100.00
					Total Mitchell Cancer Institute

**South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2020 - September 30, 2021**

Department	Project Number	Project Title	Principal Investigator	Source of Funding	20-21 Receipts
Microbiology					
	63883	Evaluation of Nanoparticle Formulations of Antiviral Drugs Against SARS-CoV-2 (Hillstream Bio SARS-CoV-2)	Dr Rayner, J	Hillstream Biopharma, Inc.	9,041.21
	63884	Aqua Resources Kill Curve for SARS-CoV-2 Virus (Aqua Resources SARS-CoV-2)	Dr Rayner, J	Aqua Resources Corp	4,454.22
	63892	Evaluation of HCB-1218 in a Hamster Model of SARS-CoV-2 (Hillstream Bio HCB-1218)	Dr Rayner, J	Hillstream Biopharma, Inc.	22,896.90
	63893	The acquisition and characterization of two recent genetic variants of SARS-CoV-2 virus. (Blue Willow SARS-CoV-2)	Dr Kim, J	Blue Willow Biologics	11,986.60
	63900	The preparatin of 2 SARS-CoV-2 vaccines using nanoemulsion adjuvant and testing the efficacy of those vaccines against challenge with up to two SARS-CoV-2 strains in a hamster model. (Blue Willow Hamster Study)	Dr Rayner, J	Blue Willow Biologics	78,018.60
				Total Microbiology	126,397.53
				Total All Departments	499,487.72
Other Research Related Revenue					
	62648	Royalty On Sales of Antibody Products	Dr Scammell, J	QED Bioscience	4,575.83
				Total Other Research	4,575.83
				Total	504,063.55